Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1982 Jun;69(6):1366–1372. doi: 10.1172/JCI110576

Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects

Paola Patrignani 1, Paola Filabozzi 1, Carlo Patrono 1
PMCID: PMC370209  PMID: 7045161

Abstract

Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective of platelet thromboxane (TX) synthesis inhibition in man. We determined the dose dependence, cumulative nature and selectivity of aspirin effects on platelet TXB2 and renal prostaglandin (PG) and prostacyclin (PGI2) production. We measured, by radioimmunoassay, serum TXB2 levels after whole blood clotting and urinary excretion of PGE2, PGF2α, and 6-keto-PGF1α, before and after single or repeated oral aspirin doses given to 46 healthy subjects. Single doses of 6-100 mg aspirin resulted in a linear (r = 0.92, P < 0.01) inhibition of platelet TXB2 production, ranging from 12 to 95% after 24 h. A daily dose of 0.45 mg/kg given for 7 d produced a cumulative and virtually complete inhibition of platelet TXB2 production, without significantly reducing the urinary excretion of PGE2, PGF2α, and 6-keto-PGF1α in both healthy men and women. The platelet inhibitory effect of this regimen was maintained unaltered throughout 1 mo of therapy, with no evidence of cumulative inhibition of renal PG-synthesis. Moreover, furosemide-induced renal PGI2 synthesis and renin release were unaffected by chronic low-dose aspirin. Following cessation of aspirin therapy, platelet TXB2 production returned toward control values at a similar rate as after a single higher dose.

We conclude that in healthy subjects: (a) aspirin causes a dose-dependent inhibition of platelet TXA2 production, with no obvious sex-related difference; (b) the inhibitory effect of daily low-dose aspirin is cumulative on platelet TXA2 but not on renal PG-synthesis; (c) during chronic low-dose aspirin therapy, renal PGI2-producing cells are readily activable by furosemide at a time of virtually complete suppression of platelet cyclooxygenase activity.

Full text

PDF
1366

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burch J. W., Stanford N., Majerus P. W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314–319. doi: 10.1172/JCI108941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Christ-Hazelhof E., Nugteren D. H. Prostacyclin is not a circulating hormone. Prostaglandins. 1981 Nov;22(5):739–746. doi: 10.1016/0090-6980(81)90213-6. [DOI] [PubMed] [Google Scholar]
  3. Ciabattoni G., Pugliese F., Cinotti G. A., Stirati G., Ronci R., Castrucci G., Pierucci A., Patrono C. Characterization of furosemide-induced activation of the renal prostaglandin system. Eur J Pharmacol. 1979 Dec 7;60(2-3):181–187. doi: 10.1016/0014-2999(79)90217-6. [DOI] [PubMed] [Google Scholar]
  4. Ciabattoni G., Pugliese F., Spaldi M., Cinotti G. A., Patrono C. Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine. J Endocrinol Invest. 1979 Apr-Jun;2(2):173–182. doi: 10.1007/BF03349310. [DOI] [PubMed] [Google Scholar]
  5. Dunn M. J., Zambraski E. J. Renal effects of drugs that inhibit prostaglandin synthesis. Kidney Int. 1980 Nov;18(5):609–622. doi: 10.1038/ki.1980.179. [DOI] [PubMed] [Google Scholar]
  6. Edlund A., Bomfim W., Kaijser L., Olin C., Patrono C., Pinca E., Wennmalm A. Pulmonary formation of prostacyclin in man. Prostaglandins. 1981 Aug;22(2):323–332. doi: 10.1016/0090-6980(81)90046-0. [DOI] [PubMed] [Google Scholar]
  7. FitzGerald G. A., Brash A. R., Falardeau P., Oates J. A. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981 Nov;68(5):1272–1276. doi: 10.1172/JCI110373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Frölich J. C., Wilson T. W., Sweetman B. J., Smigel M., Nies A. S., Carr K., Watson J. T., Oates J. A. Urinary prostaglandins. Identification and origin. J Clin Invest. 1975 Apr;55(4):763–770. doi: 10.1172/JCI107987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gryglewski R. J., Korbut R., Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature. 1978 Jun 29;273(5665):765–767. doi: 10.1038/273765a0. [DOI] [PubMed] [Google Scholar]
  10. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  11. Hanley S. P., Bevan J., Cockbill S. R., Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet. 1981 May 2;1(8227):969–971. doi: 10.1016/s0140-6736(81)91733-5. [DOI] [PubMed] [Google Scholar]
  12. Harris W. H., Salzman E. W., Athanasoulis C. A., Waltman A. C., DeSanctis R. W. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977 Dec 8;297(23):1246–1249. doi: 10.1056/NEJM197712082972302. [DOI] [PubMed] [Google Scholar]
  13. Hassid A., Dunn M. J. Microsomal prostaglandin biosynthesis of human kidney. J Biol Chem. 1980 Mar 25;255(6):2472–2475. [PubMed] [Google Scholar]
  14. Masotti G., Galanti G., Poggesi L., Abbate R., Neri Serneri G. G. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979 Dec 8;2(8154):1213–1217. doi: 10.1016/s0140-6736(79)92334-1. [DOI] [PubMed] [Google Scholar]
  15. Moncada S., Korbut R., Bunting S., Vane J. R. Prostacyclin is a circulating hormone. Nature. 1978 Jun 29;273(5665):767–768. doi: 10.1038/273767a0. [DOI] [PubMed] [Google Scholar]
  16. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 Feb 1;17(3-4):317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
  17. Patrono C., Ciabattoni G., Pugliese F., Pinca E., Castrucci G., De Salvo A., Satta M. A., Parachini M. Radioimmunoassay of serum thromboxane B2: a simple method of assessing pharmacologic effects on platelet function. Adv Prostaglandin Thromboxane Res. 1980;6:187–191. [PubMed] [Google Scholar]
  18. Patrono C., Pugliese F., Ciabattoni G., Patrignani P., Maseri A., Chierchia S., Peskar B. A., Cinotti G. A., Simonetti B. M., Pierucci A. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest. 1982 Jan;69(1):231–239. doi: 10.1172/JCI110435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Plotz P. H., Kimberly R. P. Acute effects of aspirin and acetaminophen on renal function. Arch Intern Med. 1981 Feb 23;141(3 Spec No):343–348. doi: 10.1001/archinte.141.3.343. [DOI] [PubMed] [Google Scholar]
  20. Preston F. E., Whipps S., Jackson C. A., French A. J., Wyld P. J., Stoddard C. J. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med. 1981 Jan 8;304(2):76–79. doi: 10.1056/NEJM198101083040203. [DOI] [PubMed] [Google Scholar]
  21. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shuman M. A., Levine S. P. Relationship between secretion of platelet Factor 4 and thrombin generation during in vitro blood clotting. J Clin Invest. 1980 Feb;65(2):307–313. doi: 10.1172/JCI109673. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES